LOGIN  |  REGISTER
Viking Therapeutics

TruBridge Announces Participation in the Truist Securities Healthcare Disruptors & Digital Health Conference

June 10, 2025 | Last Trade: US$22.85 0.19 0.84

MOBILE, Ala. / Jun 10, 2025 / Business Wire / TruBridge, Inc. (NASDAQ:TBRG), a healthcare technology and services company, today announced that management will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference, to be held in New York on June 24-25, 2025.

The panel discussion on “Optimizing Healthcare Workflows” with Chris Fowler, president and chief executive officer, will begin at approximately 3:30 p.m. Eastern Time on Wednesday, June 25, 2025.

About TruBridge

We partner with over 1,500 healthcare organizations to deliver technology-first solutions that improve access, outcomes, and operational efficiency. Backed by more than 45 years of experience, our HFMA Peer Reviewed® revenue cycle management (RCM) suite enhances transparency, productivity, and financial health across care settings. From electronic health record (EHR) integration across care settings to value-based care support, our data-driven tools connect providers, patients, and communities—driving better care and patient satisfaction. At our core, we believe in the power of community, collaboration and creating lasting value for our customers. We clear the way for care. For more information, please visit www.trubridge.com.

Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page